Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 1.00 |
| ▸ | JAK1 | P23458 | 6/20 | 1.00 |
| ▸ | JAK2 | O60674 | 4/20 | 1.00 |
| ▸ | MERTK | Q12866 | 12/20 | 0.50 |
| ▸ | TYRO3 | Q06418 | 11/20 | 0.48 |
| ▸ | FLT3 | P36888 | 6/20 | 0.48 |
| ▸ | GAS6 | Q14393 | 6/20 | 0.48 |
| ▸ | AXL | P30530 | 5/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22613102 | 1.00 | JAK3 (1.00) | JAK3JAK1JAK2MERTKTYRO3 | |
| SCHEMBL28919002 | 0.84 | JAK2 (0.72) | JAK3JAK1JAK2MERTKTYRO3 | |
| SCHEMBL30173276 | 0.84 | JAK2 (0.72) | JAK3JAK1JAK2MERTKTYRO3 | |
| SCHEMBL22620103 | 0.80 | JAK3 (0.65) | JAK3JAK1JAK2MERTKTYRO3 | |
| SCHEMBL22613143 | 0.80 | JAK1 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL29855590 | 0.80 | JAK1 (1.00) | JAK3JAK1JAK2 | |
| SCHEMBL28601415 | 0.76 | JAK1 (0.63) | JAK3JAK1JAK2MERTKTYRO3 | |
| SCHEMBL30173329 | 0.76 | JAK1 (0.63) | JAK3JAK1JAK2MERTKTYRO3 | |
| SCHEMBL22627349 | 0.76 | JAK2 (0.61) | JAK3JAK1JAK2MERTKTYRO3 | |
| SCHEMBL20956062 | 0.75 | JAK1 (0.72) | JAK3JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | ACLARIS THERAPEUTICS, INC. | 2022-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK3 2/4885JAK1 1/4885JAK2 3/4885 |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | JAK1, JAK3, JAK2 | JAK3 2/4885JAK1 1/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.